Time for a new approach to drug development for rare systemic autoinflammatory diseases

IF 29.4 1区医学 Q1 RHEUMATOLOGY

Nature Reviews Rheumatology Pub Date : 2024-04-02 DOI:10.1038/s41584-024-01108-6

Natalie M. Zitoun, Erkan Demirkaya, Raphaela Goldbach-Mansky, Micol Romano

引用次数: 0

Abstract

Despite the transformative potential of treatments for systemic autoinflammatory diseases, these conditions remain underfunded and understudied. Urgent, coordinated action among stakeholders is needed to overcome regulatory and research barriers, as is innovation and advocacy for the development of effective therapies for these rare diseases.

查看原文本刊更多论文

采用新方法开发治疗罕见系统性自身炎症疾病药物的时机已到

尽管系统性自身炎症性疾病的治疗方法具有变革潜力，但这些疾病的资金和研究仍然不足。各利益相关方亟需采取协调行动，克服监管和研究方面的障碍，同时也需要创新和宣传，以开发治疗这些罕见疾病的有效疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nature Reviews Rheumatology 医学-风湿病学

CiteScore

29.90

自引率

0.90%

发文量

137

审稿时长

6-12 weeks

期刊介绍： Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.